€ million |
|
Note |
|
2023 |
|
2022 |
|---|---|---|---|---|---|---|
Profit after tax |
|
|
|
2,834 |
|
3,339 |
Items of other comprehensive income that will not be reclassified to profit or loss in subsequent periods |
|
|
|
|
|
|
Net defined benefit liability |
|
|
|
|
|
|
Changes in remeasurement |
|
|
|
-236 |
|
1,440 |
Tax effect |
|
|
|
48 |
|
-300 |
Changes recognized in equity |
|
|
|
-187 |
|
1,140 |
Equity instruments |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
158 |
|
-34 |
Tax effect |
|
|
|
2 |
|
3 |
Changes recognized in equity |
|
|
|
160 |
|
-31 |
|
|
|
|
-28 |
|
1,109 |
Items of other comprehensive income that may be reclassified to profit or loss in subsequent periods |
|
|
|
|
|
|
Cash flow hedge reserve |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
98 |
|
-98 |
Reclassification to profit or loss |
|
|
|
-95 |
|
194 |
Reclassification to assets |
|
|
|
– |
|
– |
Tax effect |
|
|
|
-5 |
|
-5 |
Changes recognized in equity |
|
|
|
-2 |
|
91 |
Cost of cash flow hedge reserve |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
-17 |
|
-15 |
Reclassification to profit or loss |
|
|
|
22 |
|
16 |
Reclassification to assets |
|
|
|
– |
|
– |
Tax effect |
|
|
|
– |
|
10 |
Changes recognized in equity |
|
|
|
5 |
|
11 |
Currency translation difference |
|
|
|
|
|
|
Changes taken directly to equity |
|
|
|
-1,003 |
|
1,228 |
Reclassification to profit or loss |
|
|
|
-15 |
|
-71 |
Changes recognized in equity |
|
|
|
-1,018 |
|
1,157 |
|
|
|
|
-1,015 |
|
1,259 |
Other comprehensive income |
|
|
|
-1,043 |
|
2,368 |
Comprehensive income |
|
|
|
1,791 |
|
5,708 |
thereof: attributable to Merck KGaA shareholders |
|
|
|
1,783 |
|
5,696 |
thereof: attributable to non-controlling interests |
|
|
8 |
|
12 |